4 news items
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
are on track to submit a new Investigational New Drug Application for NPM-115, our high-dose exenatide implant for chronic weight management in obese
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
VANI
6 Mar 24
body functions. Investigational devices include Orion®, designed to provide artificial vision to people who are profoundly blind, and a new system
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
VANI
1 Mar 24
anticipates submitting the requested CMC information to the FDA in the first half of 2024. LIBERATE-1 is a randomized, 12-week investigation of the safety
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
VANI
28 Feb 24
submitting the requested CMC information to the FDA in the first half of 2024. LIBERATE-1 is a randomized, 12-week investigation of the safety, tolerability
- Prev
- 1
- Next